Anti-inflammatory effects of *Rubus coreanus* Miquel through inhibition of NF-κB and MAP Kinase

Jung Eun Lee1,2, Soo-Muk Cho2, Eunkyo Park1, Seung Min Lee3, Yuri Kim4, Joong Hyuck Auh5, Hyung-Kyoon Choi6, Sohee Lim7, Sung Chul Lee6,8 and Jung-Hyun Kim1,9

1Department of Home Economics Education, Chung-Ang University, 84 Heukseok-ro, Dongjak-gu, Seoul 156-756, Korea
2Functional Food & Nutrition Division, Rural Development Administration, Gyeonggi 441-853, Korea
3Department of Food and Nutrition, College of Human Ecology, Yonsei University, Seoul 120-749, Korea
4Department of Nutritional Science and Food Management, Ewha Womans University, Seoul 120-750, Korea
5Department of Food Science & Technology, Chung-Ang University, Gyeonggi 456-756, Korea
6College of Pharmacy, Chung-Ang University, Seoul 156-756, Korea
7Department of Life Science, Chung-Ang University, 84 Heukseok-ro, Dongjak-gu, Seoul 156-756, Korea

MATERIALS/METHODS: Unripe RCM ethanol extract (UE), unripe RCM water extract (UH), ripe RCM ethanol extract (RE), and ripe RCM water extract (RH) were prepared. Inflammatory response was induced with LPS treatment, and expression of pro-inflammatory mediators (iNOS, COX-2, TNF-α, IL-1β, and IL-6) and NO and PGE2 productions were assessed. To determine the anti-inflammatory mechanism of RCM, we measured NF-κB and MAPK activities. Results: UE and UH treatment significantly reduced NF-κB activation and JNK and p38 phosphorylation and reduced transcriptional activities decreased iNOS, COX-2, and pro-inflammatory cytokines expressions, and NO and PGE2 productions. RE and RH treatments reduced IL-1β and IL-6 expressions through suppressions of JNK and p38 phosphorylation. Conclusions: In this study, we showed that RCM had anti-inflammatory effects by suppression of pro-inflammatory mediator expressions. Especially, unripe RCM showed strong anti-inflammatory effects through suppression of NF-κB and MAPK activation. These findings suggest that unripe RCM might be used as a potential functional material to reduce chronic inflammatory responses.

Keywords: Cytokines, inflammation, MAPK, NF-κB, *Rubus coreanus* Miquel

INTRODUCTION

Inflammation is a protective response to pathogens such as bacteria, viruses, and parasites [1]. In inflammatory responses, macrophages are known to be one of the major immune cells involved [1,2], which are activated by several stimuli such as cytokines and viruses, and secrete pro-inflammatory mediators including nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and IL-6 [1,2]. These inflammatory mediators are critically associated with pain, fever, edema, and recruiting additional immune cells to the site of inflammation [1]. However, overproduction of inflammatory mediators is associated with tissue damage [3]. Moreover, several studies have been reported that chronic inflammatory response could increase risk of chronic inflammatory diseases (CIDs) such as cancer, diabetes, and cardiovascular disease [4-6]. Thus, inhibition of pro-inflammatory mediator release could be beneficial in attenuating the inflammatory response in chronic diseases.

Expression of pro-inflammatory mediators, including inducible NO synthase (iNOS), cyclooxygenase-2 (COX-2), and pro-inflammatory cytokines, is regulated by activation of nuclear factor-κB (NF-κB) and mitogen-activated protein kinases (MAPK) [2]. NF-κB exists as a heterodimer consisting of p65 and p50 subunits which are associated with inhibitors of p65 (IκB) in the cytoplasm as an inactive form (2,7,8). When macrophages are exposed to...
stimuli such as lipopolysaccharide (LPS). IκB is phosphorylated by IκB kinase (IKK) and NF-κB is separated from the phosphorylated IκB [2,3,7]. Separated NF-κB translocates to the nucleus and induces transcription of a variety of target genes such as iNOS, COX-2, IL-1β, and IL-6 [3,9,10]. Therefore, activation of NF-κB leads to inflammatory responses. LPS also stimulates MAPK pathways which increase pro-inflammatory cytokines expression through activator protein-1 (AP-1) activation [11,12]. MAPK activates AP-1 by phosphorylation then activated AP-1 binds to DNA to induce transcription of pro-inflammatory cytokines [12].

Rubus coreanus Miquel (RCM) has been used as one of the traditional Korean medicine for treatment of prostatism, diabetes mellitus, impotence, spermatorrhea, enuresis, and asthma [13]. Recent studies have shown that RCM reduces prostate tumor growth, kidney and stomach diseases, and rheumatoid arthritis because of high amounts of polyphenols [14-17]. Several studies reported that RCM contains high amounts of phenolic compounds including ellagic acid, gallic acid, cinnamic acid, protocatechuic acid, sangiunin H-4, sangiunin H-6, 23-hydroxytormentic acid, and nigialgchoside F1 [18-21]. Other studies have shown that dietary polyphenols reduce inflammatory responses by reducing oxidative stress [22-24]. High polyphenol containing food such as strawberries, cherries, grapes, wine, or tea, decreased PGE2 and NO production by suppression of COX-2 and iNOS expressions through reduction of oxidative stress [22-24]. Ripe and unripe RCM also has been shown to reduce inflammatory cytokines production such as TNF-α, and IL-6 in mast cells and macrophages [16,25]. In addition, ellagitannins in ripe Rubus berries decreased gastric inflammation through suppression of NF-κB pathway [26]. RCM has been used as a medicine or food depending on its maturation. Unripe RCM has been used as a traditional remedy for some chronic diseases but ripe RCM has been taken as a fruit. Both RCM has been shown to have anti-carcinogenic, anti-diabetic, and anti-inflammatory effects. However, few studies have compared their anti-inflammatory effects depending on their maturation and none of them elucidated its mechanism. Therefore, in this study, we determine the effect of RCM on inflammatory responses and its possible mechanism depending on its maturation.

**MATERIALS AND METHODS**

**Preparation of RCM extracts**

Ripe and unripe fruits of RCM were collected from May to June of 2010 in the Goseong area of South Korea and freeze-dried. Four different extracts were prepared from the fruits: i) 50% ethanol extracts of unripe fruit (UE), ii) aqueous extracts of unripe fruit (UH), iii) 50% ethanol extracts of ripe fruits (RE), and iv) aqueous extracts of ripe fruit (RH). Freeze-dried unripe or ripe fruits were pulverized and extracted in solutions of 30 grams of berries/L in distilled water or 50% ethanol by heating at 45°C for 1.5 h. Supernatants were collected and and frozen dried with a lyophilizer. The obtained RCM extracts were dissolved in dimethyl sulfoxide (DMSO) and kept at -20°C until it was used.

**Cell culture**

The murine macrophage cell line RAW 264.7 was purchased from the Korea Cell Line Bank (Seoul, Korea). Cells were cultured in DMEM containing 10% fetal bovine serum (v/v), 5% penicillin (100 U/ml), and streptomycin (100 μg/ml; Gibco TM Invitrogen, Grand Island, NY, USA) at 37°C in a humidified atmosphere of 5% CO2. RCM (400 μg/ml) was added on plated cells for 24 h, and then stimulated with 1 μg/ml of LPS (Sigma-Aldrich, St. Louis, MO, USA) for the indicated time.

**Cell viability assay**

Cells were treated with increasing doses of RCM extracts for 24 h then stimulated with 1 μg/ml of LPS for 18 h. Cell survival was determined by adding 500 μg/ml of 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to each well and incubated for another 2 h at 37°C. After removal of medium, cells were lysed with isopropanol. The absorbance of the colored solution was quantified by measuring at 450 nm with a microplate reader (Molecular Devices, Spectra MAX 340).

**Measurement of NO and PGE2 productions**

RAW 264.7 cells were pretreated with 400 μg/ml of RCM extract for 24 h then stimulated with LPS (1 μg/ml). After 18 h, NO and PGE2 levels in the culture media were determined using Nitrate/Nitrite Colorimetric Assay kits and PGE2 ELISA kits (Cayman Chemical, Ann Arbor, MI, USA), respectively.

**Measurement of pro-inflammatory cytokine production**

RAW 264.7 cells were incubated with RCM extracts for 24 h then stimulated with LPS for 18 h. Cell-free supernatants were subsequently employed in pro-inflammatory cytokine assays using mouse enzyme-linked immunosorbbent assay (ELISA) kits (R&D systems, Minneapolis, MN, USA), following protocol of the manufacturer.

**RNA preparation and RT-PCR**

RAW 264.7 cells were incubated with RCM extracts for 24 h then induced by LPS (1 μg/ml) for 4 h. Total RNA from LPS-induced RAW 264.7 cells was prepared using RNeasy mini kits (QIAENGA, Valencia, CA, USA) according to manufacturer’s protocol and stored at -80°C before use. Total RNA was reverse-transcribed with Super Script First Strand Synthesis Systems kits (Invitrogen, Carlsbad, CA, USA) to obtain cDNA. All PCR analyses using a thermal cycler (Bioer Technology Co., LTD, Hangzhou, China) were subsequently carried out in a 20 μl volume containing 10 μl of SYBR Green, 100 pmol of 5' and 3' primers, and cDNA. PCR primers used in this study are the following: INOS: 5'-AGTGGGTGTGTCTTTCCTC-3' (forward) and 5'-GGTTGCCCTATCTGGC-3' (reverse); COX-2: 5'-GGTCTGGTGGCCTGTGC-3' (forward) and 5'-CTCCTATGAGTAGTGCCT-3' (reverse); TNF-α: 5'-AGAGCCTAATGACCTCGGC-3' (forward) and 5'-AGATAG CAAATCGGCTGACG-3' (reverse); IL-1β: 5'-AATCTATACCTGTCCT-3' (forward) and 5'-GGTGGTCTGGCCTGTGC-3' (reverse); iNOS: 5'-AGTGGTGTTCTTTGCTTC-3' (forward) and 5'-GCTTGCCT ATACTGGTC-3' (reverse); IL-6: 5'-CTCCTATGAGTAGTGCCT-3' (forward) and 5'-AGATAG CAAATCGGCTGACG-3' (reverse); IL-1β: 5'-AATCTATACCTGTCCT-3' (forward) and 5'-AGATAG CAAATCGGCTGACG-3' (reverse); GAPDH: 5'-CCATCACCAC TCCAGGAGCG-3' (forward) and 5'-AGAGATGATTACCCCTTTT GC-3' (reverse). After amplification, a portion of the PCR products were electrophoresed on 1% agarose gel and visualized under...
UV after ethidium bromide staining.

Western blot analysis

After RCM treatments, cells were stimulated with LPS and lysated in RIPA lysis buffer containing cocktail protease inhibitors and phosphatase inhibitors (Sigma-Aldrich, St. Louis, MO, USA). Immunoblot assay was carried out as described previously [27] with antibodies against iNOS, COX-2, p-IκB, ERK 1/2, p-ERK 1/2, p38, p-p38, JNK, p-JNK, and β-actin from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Nuclear extraction and NF-κB transcriptional activity assay

RAW 264.7 cells were harvested after 24 h RCM treatment and subsequent LPS stimulation for 20 min. Nuclear proteins were extracted using a Nuclear Extraction kit (Cayman, Ann Arbor, MI, USA), and NF-κB transcriptional activity was measured using an NF-κB transcriptional factor assay kit (Cayman, Ann Arbor, MI, USA). Two micrograms of extracted nuclear proteins were incubated overnight at 4°C and p65 primary antibody was incubated. After wash, secondary antibodies were incubated and developed with transcription factor developing solution. The absorbance of the colored solution was quantified by measuring at 450 nm with a microplate reader (Molecular Devices, Spectra MAX 340).

Statistical analysis

All data are presented as means ± standard error (SE) from at least three independent experiments. Data were statistically analyzed using one-way analysis of variance (ANOVA), followed by Duncan’s multiple range test using SPSS Statistics V.17.0. A value of P < 0.05 was considered statistically significant.

RESULTS

Non-cytotoxic level of RCM on RAW 264.7 cells

To avoid any cytotoxic effect caused by RCM, we investigated the effects of RCM extracts on cell viability in RAW 264.7 using MTT assays (Fig. 1). RCM extract had no effect on cell viability except for UE, which slightly increased cell viability at 200 μg/ml.

Effects of RCM on LPS-induced NO production and iNOS expressions in RAW 264.7 cells

To investigate the effects of RCM on LPS-induced NO production and iNOS expression, cells were treated with 400 μg/ml of RCM extract for 24 h then stimulated with 1 μg/ml of LPS for 18 h. As shown in Fig. 2A, RCM treatment significantly reduced NO production compared to LPS-stimulated control. In addition, RCM pretreatments significantly reduced mRNA as well as protein expression of iNOS compared to LPS-stimulated control (Fig. 2B and 2C).

Effects of RCM on LPS-induced PGE2 production and COX-2 expressions RAW 264.7 cells

We attempted to determine whether RCM extracts modulated LPS-induced productions of PGE2 and COX-2 expression. Unripe RCM treatment significantly reduced PGE2 production by about
Effects of RCM on LPS-induced TNF-α, IL-1β, and IL-6 productions and expressions

Next, we determine the effect of RCM on pro-inflammatory cytokine expression (Fig. 4). In TNF-α production, only UE treatment significantly decreased mRNA (Fig. 4A) and protein expression compared to LPS-stimulated control (Fig. 4B).
Fig. 5. Effects of RCM extracts on NF-κB activity (A), IκB phosphorylation (B) and MAP kinase activities (C) in LPS induced RAW 264.7. Cells were treated with UE, UH, RE and RH (400 µg/ml) for 24 h then stimulated with LPS (1 µg/ml) for 20 min (A and C) or 15 min (B). NF-κB activity and relative IκB phosphorylation were measured by NF-κB (p65) transcription factor assay kit (A) and western blot (B) and MAP kinase activity was measured by western blot (C). Values not sharing the same letter were significantly different (P < 0.05).

However, UH, RE, and RH treatment had no effects on TNF-α production. RCM extract significantly decreased IL-1β and IL-6 expressions compared to LPS-stimulated control (Fig. 4C, 4D, 4E, and 4F). These results suggest that the inhibitory effects of RCM on the LPS-induced production of pro-inflammatory cytokines are regulated at the transcriptional level.

Effects of RCM on LPS-induced NF-κB and MAP kinase activities

Since inflammatory mediator expressions are activated by NF-κB and MAP kinase activities, we tested whether these activities are modulated by RCM extract (Fig. 5). RAW 264.7 cells were treated with RCM for 24 h before 20 min of LPS stimulation. LPS-induced NF-κB activities were significantly decreased when cells were pretreated with unripe RCM (Fig. 5A). Especially, UE treatment reduced NF-κB activity by about 50% compared to LPS-stimulated control. However, ripe RCM treatment had no such effect. Furthermore, considering LPS-induced NF-κB activation requires degradation of IκB, we investigated cytosolic phosphorylated IκB protein expression in RAW 264.7 cells (Fig. 5B). Cytosolic p-IκB proteins were less detected in UE- and UH-treated macrophage cells, but RE and RH treatment had no effect on IκB phosphorylation. Since pro-inflammatory cytokines are transcriptionally regulated by MAP kinases activities, we also measured 3 different MAP kinases, extracellular signal-regulated kinase 1/2 (ERK 1/2), MAPK p38, and c-Jun N-terminal kinase (JNK), phosphorylation levels (Fig. 5C). Unripe and ripe RCM significantly reduced JNK and p38 phosphorylation but had no effects on ERK1/2 activation. Unripe and ripe RCM treatment showed about 20–25% reduction of JNK phosphorylation and 60% reduction of p38 phosphorylation. These data indicated that unripe RCM reduced pro-inflammatory mediator expression through suppression of NF-κB and MAP kinase activities but ripen RCM only decreased two MAP kinases, JNK and p38, phosphorylation.

DISCUSSION

Since RCM has been shown to have high amounts of polyphenols and has been used as a traditional remedy for some CIDs, we determined the anti-inflammatory effects of RCM and their possible mechanisms using LPS-induced RAW 264.7 cells. In this study, we showed that unripe RCM (UE and UH) significantly reduced pro-inflammatory mediator expressions through suppression of NF-κB activity and MAP kinase activities.

We demonstrated that unripe RCM (UE and UH) showed stronger reduction of pro-inflammatory mediator production compared to ripe RCM (RE and RH). Several studies have reported that during maturation of RCM, amounts of polyphenols...
sensitive enzymes such as guanylate cyclase [35-37]. However, in the induction biological response by activation of NO-generated in the body has cytotoxicity activity and is involved [34,35]. Activated macrophages generate large amounts of NO and iNOS and COX-2 mRNA and protein expressions. NO is a reaction catalyzed by an NOS. Three different NOS isoforms and iNOS and COX-2 mRNA and protein expressions. NO is a compound of unripe RCM, nigaichigoside F1 was present at (2.5 times) compared to ripe RCM [21]. Moreover, active compounds of unripe RCM, nigaligicoside F1 was present at approximately 2.5% (w/dried w). However, ripe RCM contained more of anthocyanins (4.1 g/100 g of dried weight) and cyaniding compared to unripe RCM [21]. Polyphenols are known as excellent anti-oxidants and have been shown to have anti-inflammatory effects [19,28,30]. Therefore, unripe RCM, containing higher amounts of polyphenolic compounds, showed stronger anti-inflammatory response than ripe RCM.

In this study, we also showed that unripe RCM reduced pro-inflammatory mediator expressions through suppression of NF-κB activity, and MAP kinases, JNK and p38, activities. NF-κB, a transcriptional factor, regulates expression of pro-inflammatory mediators including iNOS, COX-2, and pro-inflammatory cytokines, and NF-κB activity is regulated by phosphorylation of IκB [2]. Unripe RCM significantly reduced phosphorylation of IκB, which blocked NF-κB translocation into nucleus and reduced pro-inflammatory mediators and cytokines expressions. In addition, unripe RCM significantly reduced MAP kinase phosphorylation. Several studies have shown that pro-inflammatory mediator expressions are regulated by phosphorylation of MAP kinase families such as ERK 1/2, p38, and JNK [31]. Phosphorylated MAP kinase activates AP-1 consisting of c-Jun and c-Fos, and then activates AP-1, a transcriptional factor that regulates inflammatory responses via modulation of expression of inflammatory mediator [31-33]. Other studies also showed that RCM inhibited inflammatory response through reduction of NF-κB and MAPK activity in mast cells and gastric cells [25,26]. Shin et al. reported that ripe RCM attenuated allergic inflammation such as histamine release, passive cutaneous anaphylaxis, and cytokine productions through inhibition of NF-κB and MAPK activities [25]. Moreover, Agli et al. showed that ellagitannins in Rubus berries was the anti-inflammatory compound and ellagitannins suppressed gastric inflammation through decrease of NF-κB translocation [26]. In this study, we showed that unripe RCM reduced pro-inflammatory mediator expression through suppression of NF-κB activity as well as MAP kinases, JNK and p38, activities. However, even though ripe RCM (RE and RH) reduced IL-1β and IL-6 production, it only modulated JNK and p38 phosphorylation but not NF-κB activities in macrophages. These results suggest that effects of anti-inflammatory response of RCM are differently modulated depending on cell lines or tissues.

Unripe RCM significantly reduced NO and PGE2 production, and iNOS and COX-2 mRNA and protein expressions. NO is a high reactive molecule that is synthesized from L-arginine in a reaction catalyzed by an NOS. Three different NOS isoforms have been identified [34], among which iNOS is known to be the most important in regulation of inflammatory responses [34,35]. Activated macrophages generate large amounts of NO by iNOS induction until the enzyme is degraded [35-37]. NO generated in the body has cytotoxicity activity and is involved in the induction biological response by activation of NO-sensitive enzymes such as guanylate cyclase [35-37]. However, overproduction of NO could be one of the causes of inflammatory disorder by suppressing growth of lymphocytes and damaging other normal cells and tissues [34,35,37]. PGE2 is also an inflammatory mediator and is produced by COXs. COX exists in two forms; COX-1 is expressed in almost all tissues and associated with blood flow, whereas COX-2 is dramatically up-regulated during inflammation and induces inflammatory responses such as fever and vasodilation by generating PGE2 [38,39]. COX-2 converts arachidonic acid to prostanooids such as prostaglandins, prostacyclins and thromboxanes [40], and over production of PGE2 has been implicated in the pathology of several CIDs [41]. Since iNOS and COX-2 are key mediators of inflammation, unripe RCM could be used as an anti-inflammatory reagent.

Ethanol extract of unripe RCM significantly reduced pro-inflammatory cytokine expressions. Other RCM extracts significantly decreased IL-1β and IL-6 expressions but not TNF-α expression. TNF-α, IL-1β and IL-6 are key cytokines for inflammation induction in macrophages [42]. These pro-inflammatory cytokines are involved in inflammatory responses such as generation of fever, induction of COX-2 expression, increase of PGE2 production, and promoting of immune cell differentiation [43]. However, sustained production of pro-inflammatory cytokines recruit immune cells to the site of inflammation and amplify the inflammatory state, thereby increasing risk of CIDs [3]. In this study, we found that LPS highly stimulated pro-inflammatory cytokines but RCM extracts selectively inhibited cytokine expression. These results suggest that RCM, especially unripe RCM, possesses useful anti-inflammatory activity through inhibition of pro-inflammatory cytokine production.

In this study, we showed that RCM can reduce expression and production of several inflammatory mediators, and unripe RCM (UE and UH) more effectively inhibits inflammatory responses compared to ripe RCM (RE and RH) via suppression of NF-κB activation and MAP kinases phosphorylation. Therefore, these results suggest that unripe RCM might be used for treatment of CIDs. Since sulfasalazine or glucocorticoids are widely used for treatment of CIDs, but are known to have side-effects such as fatigue, stomach pain, diarrhea, and osteoporosis [44-46]. Thus, many studies have been focused on natural products to safely suppress inflammation via suppression of NF-κB activation and/or MAP kinases activities [47]. Therefore, RCM which has been used as a traditional remedy, might be used as a potential functional material for prevention and treatment of CIDs because of its anti-inflammatory effects.

REFERENCES

1. Laroux FS. Mechanisms of inflammation: the good, the bad and the ugly. Front Biosci 2004;9:3156-62.
2. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336: 1066-71.
3. Blackwell TS, Christman JW. The role of nuclear factor-kappa B in cytokine gene regulation. Am J Respir Cell Mol Biol 1997;17:3-9.
4. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-kappa B as the matchmaker. Nat Immunol 2011;12:715-23.
5. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ,
Offenbacher S, Azambuja MI, Tracy RP, Heiss G. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999;353: 1649-52.

6. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.

7. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001;107:7-11.

8. Lee JI, Burckart GJ. Nuclear factor kappa B: important transcription factor and therapeutic target. J Clin Pharmacol 1998;38:981-93.

9. Brockman JA, Scherer DC, McKinsey TA, Hall SM, Qi X, Lee WY, Ballard DW. Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation. Mol Cell Biol 1995;15:2809-18.

10. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol 1994;10:405-55.

11. Chen C, Chen YH, Lin WW. Involvement of p38 mitogen-activated protein kinase in lipopolysaccharide-induced iNOS and COX-2 expression in J774 macrophages. Immunology 1999;97:124-9.

12. Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal 2001;13:85-94.

13. Kim EJ, Lee YJ, Shin HK, Park JH. Induction of apoptosis by the aqueous extract of Rubus coreanus in HT-29 human colon cancer cells. Nutrition 2005;21:1141-8.

14. Ra JC, Lee HY, Choi MK, Park HG, Kang KS. Effect of decreasing body weight with plant extracts containing Rubi fructus. J Toxicol Public Health 2004;20:167-72.

15. Yang HM, Oh SM, Lim SS, Shin HK, Oh YS, Kim JK. Antiinflammatory activities of Rubus coreanus depend on the degree of fruit ripening. Phytother Res 2008;22:102-7.

16. Yang HM, Lim SS, Lee YS, Shin HK, Oh YS, Kim JK. Comparison of the anti-inflammatory effects of the extracts from Rubus coreanus and Rubus occidentalis. Korean J Food Sci Technol 2007;39:342-7.

17. Kim Y, Kim J, Lee SM, Lee HA, Park S, Kim Y, Kim JH. Chemo-preventive effects of Rubus coreanus Miquel on prostate cancer. Biosci Biotechnol Biochem 2012;76:737-44.

18. Kim YH, Choi JH, Rim HK, Kang HJ, Chang SG, Park JH, Park HJ, Choi JW, Kim SD, Lee KT. 23-Hydroxytoxtermic acid and nigalichooside (f1) isolated from Rubus coreanus attenuate cisplatin-induced cytotoxicity by reducing oxidative stress in renal epithelial LLC-PK1 cells. Biol Pharm Bull 2011;34:906-11.

19. Lee J, Dossett M, Finn CE. Rubus fruit phenolic research: the good, the bad, and the confusing. Food Chem 2012;130:785-96.

20. Pang KC, Kim MS, Lee MW. Hydrolyzable tannins from the fruits of Rubus coreanus. Korean J Pharmacogn 1996;27:366-70.

21. Kim HS, Park SJ, Hyun SH, Yang SO, Lee J, Auh JH, Kim JH, Cho SM, Marriott PJ, Choi HK. Biochemical monitoring of black raspberry (Rubus coreanus Miquel) fruits according to maturation stage by 1H-NMR using multiple solvent systems. Food Res Int 2011;44: 1977-88.

22. Ellis CL, Edirisinghe I, Kappagoda T, Burton-Freeman B. Attenuation of meal-induced inflammatory and thrombotic responses in overweight men and women after 6-week daily strawberry (Fragaria) intake. A randomized placebo-controlled trial. J Atheroscler Thromb 2011;18:318-27.

23. Terra X, Montagut G, Bustos M, Llopiz N, Ardévol A, Bladé C, Fernández-Larrea J, Pujadas G, Salvadó J, Arola L, Blay M. Grape-seed procyanidins prevent low-grade inflammation by modulating cytokine expression in rats fed a high-fat diet. J Nutr Biochem 2009;20:210-8.

24. Seymour EM, Lewis SK, Urcuyo-Llanes DE, Tanone II, Kirakosyan A, Kaufman PB, Bolling SF. Regular tart cherry intake alters abdominal adiposity, adipose gene transcription, and inflammation in obesity-prone rats fed a high fat diet. J Med Food 2009;12:935-42.

25. Kim HH, Choi PH, Yoo JS, Jeon H, Chae BS, Park JS, Kim SH, Shin TY. Ripe fruit of Rubus coreanus inhibits mast cell-mediated allergic inflammation. Int J Mol Med 2012;29:303-10.

26. Sangiovanni E, Vrhovsek U, Rossoni G, Colombo E, Brunelli C, Brembati L, Trivulzio S, Gaspersi M, Mattivi F, Bessis E, Delfi A, Ellagi M. Ellagitannins from Rubus berries for the control of gastric inflammation: in vitro and in vivo studies. PLoS One 2013;8:e71762.

27. Lin Q, Lee YJ, Yun Z. Differentiation arrest by hypoxia. J Biol Chem 2006;281:30678-83.

28. Kim JM, Shin M. Characteristics of Rubus coreanus Miq. Fruits at different ripening stages. Korean J Food Sci Technol 2011;43:341-47.

29. Wang SY, Lin HS. Antioxidant activity in fruits and leaves of blackberry, raspberry, and strawberry varies with cultivar and developmental stage. J Agric Food Chem 2000;48:140-6.

30. González R, Ballester I, López-Posadas R, Suárez MD, Zarruelo A, Martínez-Augustin O, Sánchez de Medina F, Effects of flavonoids and other polyphenols on inflammation. Crit Rev Food Sci Nutr 2011;51:331-62.

31. Herlaar E, Brown Z, p38 MAPK signalling cascades in inflammatory disease. Mol Med Today 1999;5:439-47.

32. Fujioka S, Niu J, Schmidt C, Scabas GM, Peng B, Uwagawa T, Li Z, Evans DB, Abbruzzese JL, Chiao PJ. NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity. Mol Cell Biol 2004;24:7806-19.

33. Whitmarsh AJ, Davis RJ. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med (Berl) 1996;74:589-607.

34. Korhonen R, Lahti A, Kankaanrantta H, Moilanen E. Nitric oxide production and signaling in inflammation. Curr Drug Targets Inflamm Allergy 2005;4:471-9.

35. Nussler AK, Billiar TR. Inflammation, immunoregulation, and inducible nitric oxide synthase. J Leukoc Biol 1993;54:171-8.

36. Kleinert H, Pautz A, Linker K, Schwarz PM. Regulation of the expression of inducible nitric oxide synthase. Eur J Pharmacol 2004;500:255-66.

37. MacMicking J, Xie QW, Nathan C. Inducible nitric oxide synthase. Annu Rev Immunol 1997;15:323-50.

38. Murakami A, Ohigashi H. Targeting NOX, INOS and COX-2 in inflammatory cells: chemoprevention using food phytochemicals. Int J Cancer 2007;121:2357-63.

39. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Ven TT. Nitric oxide and macrophage function. Annu Rev Immunol 1997;15:323-50.

40. Lin CC, Lee IT, Yang YL, Lee CW, Kou YR, Yang CM. Induction of COX-2/PGE(2)/IL-6 is crucial for cigarette smoke extract-induced
40. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM. Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology 2000;119:1209-18.
41. Willoughby DA, Moore AR, Colville-Nash PR. COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet 2000;355:646-8.
42. Tao JY, Zheng GH, Zhao L, Wu JG, Zhang XY, Zhang SL, Huang ZJ, Xiong FL, Li CM. Anti-inflammatory effects of ethyl acetate fraction from Melilotus suaveolens Ledeb on LPS-stimulated RAW 264.7 cells. J Ethnopharmacol 2009;123:97-105.
43. Feghali CA, Wright TM. Cytokines in acute and chronic inflammation. Front Biosci 1997;2:d12-26.